Hinge Health, Inc.
NYSE:HNGEMedical - Healthcare Information Services
-$0.24 today
- Market cap
- $9.31B
- Beta
- 1.99
- P/E (TTM)
- -10.3
- EPS (TTM)
- -$6.49
Volume 1.23M
Average 1.34M
HNGE EBITDA Margin
EBITDA as a percentage of revenue.
Hinge Health, Inc.NYSE: HNGE
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 21.4%
EBITDA Margin was 21.4% in Q2 FY2026, up 437.9 pp from a year earlier. On a trailing-twelve-month basis it was 14.4%, up 127.7 pp year over year.
Context
- EBITDA Margin widened in 1 of the last 2 fiscal years.
- FY2025 was the lowest level in the 3 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 12 analysts of 30.3% for the fiscal year ending Dec 2026, up from -91.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 21.4%+3.1 pp QoQ
- Last fiscal yearDec 2025
- -91.2%-86.4 pp YoY
- LTMJun 2026
- 14.4%+127.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +437.9 pp | +32.2 pp | -405.7 pp |
| 1 year | -86.4 pp | +121.4 pp | +207.8 pp |
| 3 years | — | +124.0 pp | — |
| 5 years | +120.0 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -91.2%
- Year-over-year change
- -86.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -91.2% | -86.4pp |
| FY2024 | 2024-12-31 | -4.7% | +37.9pp |
| FY2023 | 2023-12-31 | -42.7% | — |
EBITDA Margin vs competitors
How HNGE compares with its peers on the latest reported figures
- HNGE's LTM Jun 2026 EBITDA Margin of 14.4% is the 2nd highest of the 5 companies compared; the peer median is 7.2%.
- Its year-over-year change of +127.7 pp is the highest of 5, against a peer median of -0.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 21.7% | -1.3 pp | -0.4 pp | |
| LTM Jun 2026 | 14.4% | +127.7 pp | — | |
| LTM Mar 2026 | 14.2% | +0.5 pp | +0.3 pp | |
| LTM Mar 2026 | 0.2% | +15.0 pp | +69.9 pp | |
| LTM Apr 2026 | -32.8% | -10.9 pp | -52.4 pp | |
| Peer median (excluding HNGE) | 7.2% | -0.4 pp | -0.0 pp | |
Competitors are the stored peer set for HNGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 292.73M | 390.4M | 587.86M |
| Cost of Revenue | 98.55M | 89.81M | 118.56M |
| Gross Profit | 194.18M | 300.59M | 469.3M |
| Gross Margin | 66.3% | 77.0% | 79.8% |
| Research & Development | 110.06M | 100.84M | 368.14M |
| Selling, General & Admin | 214.64M | 227.54M | 639.41M |
| Operating Expenses | 324.69M | 332.5M | 1.02B |
| Depreciation & Amortization | 5.63M | 5.95M | 5.13M |
| EBITDA | (124.89M) | (18.48M) | (535.89M) |
| EBITDA Margin | -42.7% | -4.7% | -91.2% |
| Operating Income | (130.51M) | (31.91M) | (546.37M) |
| Operating Margin | -44.6% | -8.2% | -92.9% |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 21.97M | 20.65M | 19.11M |
| Income Before Tax | (108.55M) | (11.26M) | (527.26M) |
| Pre-Tax Margin | -37.1% | -2.9% | -89.7% |
| Income Tax Expense | (405K) | 677K | 998K |
| Net Income | (108.14M) | (11.93M) | (528.26M) |
| Net Margin | -36.9% | -3.1% | -89.9% |
| EPS (Basic) | (1.39) | (0.15) | (5.36) |
| EPS (Diluted) | (1.39) | (0.15) | (5.19) |
| Weighted Avg Shares | 78.02M | 78.02M | 79.19M |
| Weighted Avg Shares (Diluted) | 78.02M | 78.02M | 81.7M |
Hinge Health, Inc.
NYSE:HNGE
Intrinsic Alpha fair value
Locked
Current Price
$114.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.